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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S47532.3). A signiﬁcant positive interaction was found between severe pain
at baseline and treatment effect (interaction coefﬁcient 13.6, 95%CI 1.4-
25.8). A non-signiﬁcant overall interaction estimate was found for
inﬂammatory signs 12.5 (95%CI -7.22-32.3). However, a strongly pos-
itive interaction estimate (45.3, 95%CI 24.4-66.1) was found for
inﬂammation and treatment effect when analyzed in the studies where
inﬂammation was measured by ultrasound.
Conclusions: Our results show that patients with severe pain at base-
line do beneﬁt signiﬁcantly more from IA glucocorticoid injections than
those with less severe pain and this could be used as a predictive
measure of response in clinical practice. However inﬂammation deﬁned
by ultrasound provided an even more signiﬁcant measure of a positive
treatment response of IA glucocorticoids in patients with knee or hip
OA. The differences in treatment response at short-term follow-up
between IA glucocorticoid treatment and IA placebo were much larger
when inﬂammatory signs, measured by ultrasound, were present
compared to absence of inﬂammatory signs.
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BONE MARROW LESIONS MAY NOT RESPOND TO ANTI-
INFLAMMATORY TREATMENTS IN KNEE OSTEOARTHRITIS(OA)
T.W. O’Neill y, M.J. Parkes y, N. Maricar y, A.D. Gait y, T.F. Cootes y,
E.J. Marjanovic y, D. Bailey z, C.E. Hutchinson z, D.T. Felson y,x. y The Univ.
of Manchester, Manchester, United Kingdom; z The Univ. of Warwick,
Coventry, United Kingdom; xBoston Univ., Boston, MA, USA
Purpose: Intra-articular steroid therapy to the knee is associated with a
reduction in pain in patients with symptomatic knee OA. The mecha-
nism by which treatment is linked with a reduction in pain is unknown
though thought in part to be related to a reduction in synovitis. Bone
marrow lesions (BMLs) are poorly circumscribed lesions of water signal
on MRI using fat suppressed pulse sequences; while BMLs may be
caused by mechanical stress across the joint, their relation to inﬂam-
mation is unknown though it is possible they may be a candidate target
for steroid therapy as they are linked with knee pain and ﬂuctuate over
time. The aim of this analysis was to determine whether intra-articular
steroid therapy is associated with a change in BMLs.
Methods: Men and women aged 40 years and older with painful knee
OA, and who met American College of Rheumatology criteria for the
disease, were recruited for participation in an ongoing open label
clinical trial of intra-articular steroid therapy. Subjects who took part in
the study had signiﬁcant knee pain and knee OA of grade 2 (Kellgren-
Lawrence) or higher. At baseline they completed also the Knee Injury
and Osteoarthritis Outcome Score (KOOS). They had a Gadolinium(Gd)-
enhanced MRI immediately prior to having an intra-articular steroid
injection with repeat questionnaire and Gd-enhanced MRI scan at the
post-injection visit usually within a 2 week period. Response was
determined using the OARSI responder criteria. Those who responded
were followed up by serial telephone call until their knee pain recurred
or at 6 months at which point a further Gd-enhanced MRI was sched-
uled. The knee images were assessed semi-quantitatively for BML
severity (score 0-45 using the WORMS method) at all three time points
by an experiencedMSK radiologist. Synovial tissue volumewas assessed
using manual segmentation and computer image analysis of the con-
trast enhanced images. We looked at mean change in BML severity
score, between baseline and post-injection visit, and themean change in
BML score between baseline and the ﬁnal scan.We looked also at change
in synovial volume between baseline and the post injection scan.
Results: 100 patients with imaging data were included in this analysis.
Their median age was 62.0 years (SD 10.4 years), and 48 were female.
The median time between baseline and post-injection scan was 8 days
(IQR 7 to 14 days). Among those who responded (67) pain recurred
within 6 months in 46. The median BML score at baseline was 8.0 (IQR
4.0 to 12.0), post-injection visit 8.0 (IQR 4.2 to 12.0) and 7 (IQR 4.0 to
10.9) at ﬁnal visit. The score did not differ between the baseline and
post-injection scan (mean within person difference ¼ 0.05 points; 95%
CI -0.21 to 0.31 points; p ¼ 0.72) however a slight difference was noted
between the baseline and ﬁnal scan (mean within person difference ¼
-0.36 points; 95% CI -0.67 to -0.06 points; p ¼ 0.02). This within-person
difference reﬂects a reduction of 4.6% in the baseline BML score, which,
while statistically signiﬁcant, is a clinically small change. In contrast,
synovial volume shrank between the baseline and post-injection visit
(mean within person difference ¼ -1082mm3; 95% CI -1996 to
-168mm3; p ¼ 0.02). This within-person difference reﬂects a reduction
of 13.2% in the baseline synovitis score.Conclusions: BMLs show little change in response to intra-articular
steroid therapy in patients with symptomatic knee OA, suggesting they
may not respond to anti-inﬂammatory treatments.
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DEVELOPMENT OF A NEW HYALURONIC ACID-CALCITONIN
CONJUGATE FOR THE LOCAL TREATMENT OF OSTEOARTHRITIS
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Purpose: Salmon calcitonin (sCT) has been shown to exert beneﬁcial
metabolic actions on cartilage and bone turnover and may therefore be
useful in the management of osteoarthritis (OA). A calcitonin-based oral
treatment for knee OA recently failed to meet the primary endpoint for
efﬁcacy in a two-year placebo-controlled clinical trial, though demon-
strating positive effects on pain and function. The objective of our
project is to synthesize a new polymeric conjugate between hyaluronic
acid (HA) and salmon calcitonin and to evaluate its potential as intra-
articular treatment for OA. The rationale is to retain sCT in the joint
cavity, thus maximizing and prolonging the local activity and avoiding
the side effects related to a systemic administration.
Methods: HA was linked to sCT by means of a spacer having pendant
aldehyde groups for selective conjugation at the N-terminus of the
peptide.
The residual activity of conjugated sCT was investigated in rats by
measuring the plasma calcium level after i.v. injection. Preliminary PK
studies were performed by labeling HA-sCT and sCT with a ﬂuorescent
dye for the detection in blood samples after i.a. injection. In addition,
blood samples were withdrawn at ﬁxed times up to 24 hours and the
total calcium levels were measured using a colorimetric calcium assay.
Unilateral OA was surgically induced in the rabbit knees by anterior
cruciate ligament transection (ACLT). Controls (PBS and HA), sCT and
HA-sCT at 25, 100 and 400 UI, were administered by i.a. injection once a
week at day 10, 17 and 24 post-surgery. The efﬁcacy was evaluated by
macroscopic examination of the treated joint, histopathological
assessment of the synovial membrane and of the femoral condyles. The
histopathological criteria score was based on the evaluation of four
parameters: articular cartilage morphology, subchondral bone mor-
phology, cartilage thickness, and arrangement of chondrocytes.
Results: The new HA-sCT conjugate was synthesized according to a
patented technology that avoids the formation of heterogeneous and
cross-linked products.
The potency of the conjugated sCT was evaluated by i.v. injection,
showing that it maintains a comparable potency with respect to the free
protein and sustains the hypocalcaemic action for a longer time.
Interestingly, after local administration, unlike free sCT, HA-sCT did not
cause a systemic reduction of calcium concentration, suggesting a
negligible extra-articular diffusion of the conjugated peptide.
The PK study with labelled sCTconﬁrmed this encouraging result: while
i.a. injection of HA-sCT led to very low and constant plasma peptide
concentration, the local administration of free sCT resulted in high
ﬂuorescence in plasma, demonstrating a fast clearance of the peptide
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hypocalcaemic effect after i.a. injection.
The efﬁcacy of the HA-sCT treatment was tested in a rabbit OA model,
where a chondroprotective effect of the highest dose tested was proven
by macro- and microscopic assessments and histological ﬁndings. The
cartilage surfaces of the weight-bearing parts, such as the medial tibial
plateau and the lateral and medial femoral condyle, were evaluated and
graded for degradation severity
The average scores on the macroscopic assessment of sCT or HA-sCT
treated group indicated a signiﬁcant reduction in cartilage damage in
comparison to controls.
PAS staining of nuclei, indicating the maintenance of chondrocyte
number, and Alcian blue staining of proteoglycan, indicating the matrix
integrity of the cartilage, were signiﬁcantly positive in the majority of
the HA-sCT treated groups.
Conclusions: The in vivo PK and efﬁcacy/safety proﬁles of sCT and HA-
sCT were examined in this study in view of a potential application in the
treatment of OA. Although the i.a. injection of the different sCT-based
formulations showed to be comparably chondroprotective in a
mechanical model of OA in vivo, the HA-peptide conjugate has the
advantage of a sustained action and of a decrease in systemic exposure
to sCT with consequent potential safety concerns. The promising results
encourage further development and investigation on this therapeutic
approach for OA.
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HYALURONIC ACID ALKYL DERIVATIVE (HYADD4) SHOWING
INHIBITORY ACTIVITY ON HYALURONIDASES
M. Pavan, D. Galesso, C. Guarise. Fidia Farmaceutici spa, Abano Terme,
Italy
Purpose: Hyaluronic Acid (HA) homeostasis in the knee is based on a
ﬁne balance between synthesis and degradation; in pathological con-
ditions, Hyaluronidases (speciﬁcally Hyal-2) play a key role in HA
catabolism. The reduction of endogenous HA Molecular Weight (MW)
and concentration in Synovial Fluid (SF) is one of the molecular signals
of Osteoarthritis (OA) progression. Viscosupplementation is an intra-
articular pharmacological therapy based on mechanical restoration of
joint performance; to date, no polymer used in viscosupplementation is
known to have an inhibitory action on Hyaluronidases. We present here
a novel series of HA alkyl-amide derivatives (HYADD) which, besides
good rheological performances, show inhibition of Hyal-2, suggesting a
possible biological effect in SF degradation.
Methods: Several unmodiﬁed and chemically modiﬁed polymers
actually used in viscosupplementation therapy were compared for their
inhibitory effect on the hyaluronidase enzymatic action towards HA.
Therefore, in presence of these polymers, HA (2000 kDa) was incubated
at 37C as a substrate for Bovine Testis Hyaluronidase (BTH) and the
resulting MW was determined by means of SEC-TDA Viscotek. In order
to avoid the physical entrapment effect, the experiment was repeated
after depolymerization of the testmaterials by heating at 105C for 24 h,
before incubation with HA. Since only the HA hexadecylamide
(HYADD4) was able to preserve the initial HA MW, a series of HA
amide derivatives with different alkyl/aryl side chains were tested in
terms of Hyaluronidase inhibition, with the aim of verifying the inﬂu-
ence of their structure on this activity. C8-, C12-, C15-, C16-, C18- and
benzyl- amide of HA were then synthesized and their IC50 versus BTH
was obtained using HA as substrate andmeasuring its MWat increasing
inhibitor concentration. HYADD-C16 (HYADD4) was selected as lead
compound on the basis of its good balance between potency and
solubility.
Finally, the activity of HYADD4 (formulated at 8 mg/ml in PBS pH 7)
was validated ex-vivo in human SFs collected by arthrocentesis from OA
patients (n ¼ 3); the SFs were not centrifuged in order to avoid the loss
of Hyal-2, located on the cell surface. HYADD4 was incubated at 37C
in the SFs (unmodiﬁed HA was used as control); after 24 h CuCl2 100
mm was added, which allowed the precipitation of proteins and the
analysis of the endogenous HA molecular weight.
Results: The MW of HA incubated with BTH in presence of 4 out of 5
polysaccharides tested dropped in just 60 min from 2000 kDa to about
400 kDa; in presence of HYADD4, even after 24 h, HA preserved its
initial MW. The results were conﬁrmed after depolymerization of the
polymer: HYADD4 was still able to completely inhibit BTH, thus pre-
venting HA cleavage.
The comparison of IC50 of the different HYADD
 derivatives highlighteda strong correlation between the alkyl chain length and the ability to
inhibit BTH. Benzyl-, C8- and C-12 derivatives showed no interaction
with the enzyme, while C15-, C16- and C18- derivatives proved to be
stronger inhibitors (IC50 of 276.5  4.7, 166.5  2.6 and 149.7  2.1 mM,
respectively). HYADD4 was therefore selected as lead compound
because of its best compromise between solubility and potency.
The ex-vivo test on OA SFs demonstrated that HYADD4 at 425 mM is
able to slow down the degradation of endogenous HA by Hyal-2, which
is markedly faster in the control test where exogenous unmodiﬁed HA
was used (n ¼ 3, P < 0.001).
Conclusions: In this study we found that some alkyl-amide derivatives
of HA (HYADD), compared to other polysaccharides used in the pro-
duction of viscosupplements, possess the unique ability to inhibit
Hyaluronidases. This property was demonstrated in vitro through the
measurement of IC50 against BTH and then conﬁrmed ex-vivo in OA SFs
for the selected lead compound, HYADD4, , which was shown to
protect endogenous HA from Hyal-2 degradation. The intra-articular
administration of the biopolymer has also the advantage of overcoming
easily the possible issues of systemic distribution and chronic toxicity,
that are common for the small molecule inhibitors.
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SELECTIVE INHIBITION OF MATRIX METALLOPROTEASE-13 BY
HYALURONIC ACID ALKYLAMIDE DERIVATIVES FOR THE INTRA-
ARTICULAR TREATMENT OF OSTEOARTHRITIS
C. Guarise, M. Pavan, D. Galesso. Fidia Farmaceutici s.p.A., Abano Terme
(PD), Italy
Purpose: In the pathophysiology of osteoarthritis (OA) several media-
tors are involved, however the attempts to develop a drug acting on
speciﬁc targets involved in OA progression (e.g. Matrix Metal-
loproteases: MMPs) failed at various stages due to unfavourable phar-
macokinetics or chronic toxicity. On the other hand Hyaluronic Acid
(HA) is widely used as an intra-articular therapy for OA thanks to its
capacity of restoring viscoelasticity and lubrication in degraded syno-
vial ﬂuid and to its beneﬁcial effects on inﬂammation and cartilage
metabolism.
We describe here the selection of a HA alkylamide derivative
(HYADD4) with inhibitory activity in the micromolar range vsMMP13,
for the intra-articular treatment of OA patients.
Methods: Chlostridium histolyticum Collagenase (ChC) was used as
model of MMP. A number of selected glycosaminoglycans currently
used in viscosupplements were compared for their inhibitory effect on
ChC enzymatic activity: Chondroitin Sulfate (CS), unmodiﬁed HA, HA
cross-linked and HA amidated with hexadecylamine, all formulated at 8
mg/ml in PBS pH 7, were incubated in presence of ChC at 37C and
samples withdrawn at different timepoints were tested in a ChC activity
assay. In order to abolish the effect of physical entrapment of the
enzyme, the test was repeated after depolymerization of the materials
by heating at 105C for 24 h before incubation with ChC.
For the screening of the modiﬁed HAs: six amide derivatives of HAwere
synthesized by alkylation at the carboxylic group of the D-Glucuronic
acid unit with a series of linear alkyl chains C8, C12, C15, C16, C18 and a
benzyl group, at the same amidation degree. The inhibition constant
(Ki) of the depolymerized HA amide derivatives, versus ChC was
measured by steady-state kinetics experiments at several inhibitor
concentration.
The compound selected as the best ChC inhibitor (HYADD-C16 or
HYADD4) was then tested in vitro vs the catalytical subunits of 10
human MMPs using a MMP Inhibitor Proﬁling Kit. The selective inhib-
itory activity of HYADD4 vsMMP13 observed in the screening test was
ﬁnally validated on the human enzyme in an ex-vivo experiment with
human inﬂamed synovial ﬂuid (SF), collected by arthrocentesis and
analyzed by means of a human MMP13 assay kit.
Results: In the ﬁrst screening test the cross-linked HA and HA hex-
adecylamide, but not CS and high MW HA, showed a relevant decrease
of the ChC activity (probe metalloprotease). In order to rule out the
hypothesis that the inhibitionwas due to simple physical entrapment of
the enzyme in the test materials, the experiment was repeated after
depolymerization of the polysaccharides: in these conditions ChC
activity was almost completely recovered in the case of cross-linked
HAs, while depolymerized HA hexadecylamide (HYADD4) caused a
further loss of enzyme activity, as a proof of speciﬁc inhibition.
Since the HA alkylamide showed this unique property, in the second
part of the work six different amide derivatives of HA, synthesized with
